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endothelial cell lipotoxicity
Hnin H Aung1†, Athanasios Tsoukalas2,3†, John C Rutledge1 and Ilias Tagkopoulos2,3*Abstract
Background: Neurovascular inflammation is associated with a number of neurological diseases including vascular
dementia and Alzheimer’s disease, which are increasingly important causes of morbidity and mortality around
the world. Lipotoxicity is a metabolic disorder that results from accumulation of lipids, particularly fatty acids, in
non-adipose tissue leading to cellular dysfunction, lipid droplet formation, and cell death.
Results: Our studies indicate for the first time that the neurovascular circulation also can manifest lipotoxicity,
which could have major effects on cognitive function. The penetration of integrative systems biology approaches is
limited in this area of research, which reduces our capacity to gain an objective insight into the signal transduction
and regulation dynamics at a systems level. To address this question, we treated human microvascular endothelial
cells with triglyceride-rich lipoprotein (TGRL) lipolysis products and then we used genome-wide transcriptional
profiling to obtain transcript abundances over four conditions. We then identified regulatory genes and their targets
that have been differentially expressed through analysis of the datasets with various statistical methods. We created
a functional gene network by exploiting co-expression observations through a guilt-by-association assumption.
Concomitantly, we used various network inference algorithms to identify putative regulatory interactions and we
integrated all predictions to construct a consensus gene regulatory network that is TGRL lipolysis product specific.
Conclusion: System biology analysis has led to the validation of putative lipid-related targets and the discovery of
several genes that may be implicated in lipotoxic-related brain microvascular endothelial cell responses. Here, we
report that activating transcription factors 3 (ATF3) is a principal regulator of TGRL lipolysis products-induced gene
expression in human brain microvascular endothelial cell.
Keywords: Activating transcription factor 3, Microarray, Triglyceride-rich lipoprotein, Blood–brain barrierBackground
The estimated prevalence of dementia of persons greater
than 70 years of age is 14.7% [1]. The yearly cost attributable
to dementia is between $43,000/patient and $70,000/patient
and the total monetary cost of dementia in 2010 was
between $157 billion and $215 billion. Add to this, the
enormous personal and emotional cost to, not only the
patient, but also to family, friends, and co-workers, and we
have a national tragedy that is about to unfold as the
baby boomers transition to the elderly. These financial* Correspondence: iliast@ucdavis.edu
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reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.and personal costs place dementia on par with the costs
attributable to ASCVD and cancers.
One of the potential inducers of neurovascular inflam-
mation is triglyceride-rich lipoprotein (TGRL) particles
and their lipolysis products [2]. Lipoprotein lipase (LpL) is
anchored to the brain microvascular endothelium, where
it binds and hydrolyzes TGRL particles to smaller lipolysis
products, such as fatty acids [3]. TGRL lipolysis products
are generated at the luminal surface of the vascular endo-
thelium and the lipolysis products in high physiological
and pathophysiological concentrations can potentially
injure the endothelium directly, increase the permeability
of the blood–brain barrier (BBB), and/or injure astrocytes
and neurons within the brain. Our studies have shown that
TGRL lipolysis products have a dramatic effect on endo-
thelial cell injury, which is of much greater magnitude than
TGRL particles, such as chylomicrons and VLDL [4].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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http://www.biomedcentral.com/1752-0509/8/80To explore neurovascular lipotoxicity further, we treated
human brain microvascular endothelial cell (HBMVEC)
with TGRL lipolysis products and then we used
genome-wide transcriptional profiling to obtain transcript
abundances over four conditions. We then identified
regulatory genes and their targets that have been differen-
tially expressed (DE) through analysis of the datasets
with various statistical methods (Figure 1). We created a
functional gene network by exploiting co-expression
observations through a guilt-by-association assumption.
Concomitantly, we used various network inference
algorithms to identify putative regulatory interactions and
we integrated all predictions to construct a consensus
gene regulatory network that is TGRL lipolysis productFigure 1 Overview of the experimental and computational procedure
four environments and their expression was normalized by using three pro
the perfectly matched and mismatched probes. Then we built the gene on
PPI network, which is available in literature, to identify implicated processe
under these conditions, we used a supervised network inference approach
find similar expression patterns in our data and thus uncover novel interactio
and their relative levels are quantified.specific. This analysis has led to the validation of putative
lipid-related targets and the discovery of several genes
that may be implicated in TGRL lipolysis-related lipid
response. Our system biology analysis also identified that
activating transcription factors 3 (ATF3) is a principal
regulator and induces expression of downstream inflam-
matory response genes in HBMVEC treated with TGRL
lipolysis products.
Results
As shown in Figure 2, there is some overlap between the
different DE techniques used, as well as differences in
the top gene candidates identified, due to the different
features and underlying statistical assumptions of eachs. Expression profiles of endothelial cells were taken after treatment in
babilistic methods that exploit the difference in the distributions of
tology and functional networks that we overlapped with the known
s and genes. To uncover putative TF-gene interactions that take place
that utilizes known information about TF genes and their targets to
ns. Finally, top ranked over/under expressions are validated by qRT-PCR
Figure 2 Venn diagrams on differentially expressed (DE) genes. (A) The most highly-ranked 550 genes from all available methods; (B) Venn
diagram shows overlap for probabilistic-only methods that were used to identify the consensus list of DE genes. The gene cut-off (550 genes)
corresponds approximately to a p-value of 0.05 or lower in all methods.
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http://www.biomedcentral.com/1752-0509/8/80technique. Table 1 depicts the top 20 genes that
have the highest DE between the treatment with the
combination of TGRL and LpL (TGRL lipolysis products),
and the control (media-only) that are within the statistical
cut-off value (p-value < 10−4), over all techniques.
Consistent with our previous results in endothelial cells
[5], ATF3 shows clear up-regulation after TGRL lipolysis
product treatment.
The 79 DE genes that have been in parallel identified
from all methods form a functional gene network
with 54 functional categories that are significantly
over-represented in this gene set, which also implicates 12
KEGG pathways (Figure 3A). We integrated the expression-
derived relationships with the known protein-protein
interaction (PPI) network that was extracted by using
the BIONET Bioconductor package [6] and the Interactome
Library [7] (Figure 3C). In addition, we used a support
vector machines (SVM) method called SIRENE [8] together
with a dataset where we amassed of all known TF-gene in-
teractions (~4000) in order to construct a condition-specificGene Regulatory Network (GRN) associated with TGRL
lipolysis treatment (Figure 4). The resulting network
has 151 TFs, 272 target genes (X and Y up- and
down-regulated, respectively), 236 inhibitory interactions
(ρ < −0.25), and 265 activatory interactions (ρ > 0.25).
Genome-wide analysis of TGRL lipolysis-treated HBMVEC
Differential analysis of gene expression data showed that
HBMVEC treated with either LpL or TGRL altered
the expression of a small percentage of genes (3.01%
and 4.03%, respectively, when compared to control).
TGRL + LpL (TGRL lipolysis products) treatment affected
the expression of 5.61% of all genes detected (~14,500).
Functional classification of genes modulated by lipolysis
product (TGRL + LpL) treatment identified multiple func-
tional classes including transcription factors, inflammatory
responses, apoptosis, cell cycle, cell proliferation, ion
metabolism, lipid metabolism, kinase activity, signalling
pathways, DNA binding, protein binding, protein folding,
and proteins of unknown function.
Table 1 Top 20 differentially expressed (DE) genes (consensus over three methods); Numbers denote the fold-change (FC)
between the TGRL + LpL condition and the control (media-only)
GENE SYMBOL GENE NAME iPPLR FC BGX FC PPLR FC p-values
ATF3 Activating transcription factor 3 1,86 2,67 3,06 10−14
BHLHE40 Basic helix-loop-helix family, member e40 0,35 0,23 0,32 10−9
PRNP Prion protein 1,47 3,09 3,89 10−8
CSGALNACT2 Chondroitin sulfate N-acetylgalactosaminyltransferase 2 1,48 3,90 4,36 10−8
ADD3 Adducin 3 (gamma) 1,61 4,29 4,52 10−7
MAD2L1 MAD2 mitotic arrest deficient-like 1 (yeast) 1,07 3,49 3,31 10−7
ADAM9 ADAM metallopeptidase domain 9 1,22 3,19 3,38 10−7
ZNF217 Zinc finger protein 217 1,83 6,04 4,94 10−7
DDIT3 DNA-damage-inducible transcript 3 1,11 2,50 2,83 10−6
STK39 Serine threonine kinase 39 1,13 2,94 3,81 10−6
LIMS1 LIM and senescent cell antigen-like domains 1 1,14 3,03 3,10 10−6
MMRN1 Multimerin 1 1,62 2,95 3,34 10−5
CSGALNACT2 Chondroitin sulfate N-acetylgalactosaminyltransferase 2 1,06 3,99 3,63 10−5
PAIP1 Poly(A) binding protein interacting protein 1 1,04 2,34 2,80 10−5
HDGFRP3 Hepatoma-derived growth factor, related protein 3 1,05 2,26 2,84 10−5
HES1 Hairy and enhancer of split 1, (Drosophila) 0,56 0,34 0,42 10−5
FRMD4B FERM domain containing 4B 1,13 2,80 2,92 10−5
DUSP6 Dual specificity phosphatase 6 1,08 3,03 2,71 10−4
PRKAR1A Protein kinase, cAMP-dependent, regulatory, type I, alpha 1,12 2,69 2,73 10−4
TTC37 Tetratricopeptide repeat domain 37 1,13 2,72 2,48 10−4
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TGRL lipolysis products activated genes encoding
transcription factors including activating transcription
factor (ATF3), ATF4, ATF2, DNA damage-inducible
transcript 3 (DDIT3), CREB binding protein (CREBBP),
Krueppel-like factor 4 (KLF4), KLF5, aryl hydrocarbon
receptor (AHR), peroxisome proliferator-activated receptor
delta (PPARD). ATF3 is a member of the mammalian
activation transcription factor/cAMP responsive element-
binding (CREB) protein and a member of the ATF family
of transcription factors. This gene is induced by a variety of
signals including many of those encountered by cancer
cells, and is involved in the complex process of cellular
stress response [9] and post-translational modifications
have been established. For instance, it has been reported
previously that upon UV irradiation, two transcription
factors, c-Jun and ATF2, are phosphorylated by the
JNK/SAPK family of stress-induced kinases [10].
Many stress responses have been studied in tissue
culture cells by using signals including UV irradiation
[11], cytokines [12], and modulated by gadd153/Chop10
[13]. ATF4 encodes a transcription factor that was
originally identified as a widely expressed mammalian
DNA binding protein. Recently it has been found that
ATF4 mediates hyperglycemia-induced endothelial
inflammation and retinal vascular leakage in mouse [14].Up-regulation of ATF3 (19.6-fold) and ATF4 (3.6-fold) by
TGRL lipolysis in HBMVEC was confirmed by qRT-PCR
(Figure 5A).
CREB binding protein (CREBBP) is ubiquitously expressed
and is involved in the transcriptional coactivation of many
different transcription factors and known to play critical
roles in embryonic development, growth control, and
homeostasis by coupling chromatin remodeling to transcrip-
tion factor recognition. Transforming growth factor-β sig-
nalling pathways mediate epithelial-mesenchymal transition
are dependent on the transcriptional co-activator CREBBP
[15]. CREBBP was increased (1.1-fold) but not significantly
up-regulated by TGRL lipolysis products (data not shown).
DNA damage-inducible transcript 3 (DDIT3; 5.6-fold up-
regulation; Figure 5A) is a member of the CCAAT/enhancer
binding proteins (C/EBPs) (CHOP) family of transcriptional
factors that regulate cell cycle and apoptosis.
Krueppel-like factor 4 (KLF4; 4-fold up-regulation;
Figure 5A) is known to be endothelial Kruppel-like zinc
finger protein. KLF4 differentially regulates pertinent
endothelial targets and important regulators of vascular
homeostasis and atherothrombosis [16]. Kruppel-like
factor 4 regulates endothelial activation in response to
pro-inflammatory stimuli [17]. Peroxisome proliferator-
activated receptor delta (PPARD or PPARδ) (0.6-fold down-
regulation; Figure 5A) is a member of the peroxisome
AB C
.
Figure 3 Functional and PPI networks related to TGRL lipolysis treatment of endothelial cells. (A) Functional gene network, (B) KEGG
pathways and (C) PPI network. Color denotes differential expression ranging from strong down-regulation (green) to strong up-regulation (red).
Solid/dashed lines are based on statistical significance (0.05).
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http://www.biomedcentral.com/1752-0509/8/80proliferator-activated receptor (PPAR) family. PPARs
mediate a variety of biological processes, and may be
involved in the development of several chronic diseases,including diabetes, obesity, atherosclerosis, and cancer.
PPARs are nuclear receptors regulating the expression of
genes involved in lipid and glucose metabolism [18,19].
Figure 4 TGRL lipolysis treatment network of differentially expressed genes. Edges denote regulatory interactions (TF-DNA binding), yellow
are transcription factor (TF) genes and red nodes are differentially regulated targets. Edge weight corresponds to the Pearson correlation coefficient ρ of
the expression profiles in connected nodes and the value of the edge (see Additional file 1: Table S1) denotes how statistically significant the interaction
is (in all cases p-value < 10−2). The resulting network has 151 TFs, 272 target genes (X and Y up- and down-regulated, respectively), 236
inhibitory interaction (ρ < −0.25), 265 activatory interactions (ρ > 0.25).
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http://www.biomedcentral.com/1752-0509/8/80PPARD is an important regulator of fatty acid (FA)
metabolism [20]. Increase expression of PPARD has
been reported in hepatic steatosis that is induced by
oleic acid. Several lines of evidence point to a negative
regulatory role for PPARβ/δ in inflammatory responses of
the skin. Thus, mice deficient for PPARβ/δ showed anincreased inflammatory response to the topical application
of O-tetradecanoylphorbol-13-acetate [21].
The Specific protein 3 gene (Sp3; 0.8-fold down-
regulation; Figure 5A) encodes for transcription factors
that regulate transcription by binding to consensus
GC- and GT-box regulatory elements in target genes.
Figure 5 Confirmation of selected genes by qRT-PCR. TGRL lipolysis products (TL) compare to Media (M) alone treatment. Genes related to
(A) Transcription factors, (B) Pro-inflammatory Response, (C) Cell cycle and Apoptosis, D) Metabolism and Signalling pathway. HBMVEC were
treated with either Media (M) or TGRL lipolysis products (TL) for 3 hr. Microarray analysis: (pooled n = 3 per GeneChip as compared to TGRL-treated
group). For qRT-PCR, the expression of each gene was normalized to that of GAPDH and then fold change was calculated as a ratio of expression after
lipolysis products treatment relative to TGRL controls (individual n = 3). An asterisk (*) denotes p-value≤ 0.05.
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http://www.biomedcentral.com/1752-0509/8/80Sp3 is an inducer of apoptosis and a marker of tumor
aggressiveness [22].
TGRL lipolysis products activate pro-inflammatory factors
Interleukin 8 (IL-8 or CXCL8; 2.4-fold up-regulation;
Figure 5B), a member of the CXC chemokine family, is
one of the major mediators of inflammatory responses.
Chemokine ligand 3 (CXCL3; 4.5-fold up-regulation;
Figure 5B), which is known to be induced by oxidized
low-density lipoprotein, was also was found to be
induced by TGRL lipolysis products. Prion protein (PRNP;
1.3-fold up-regulation; Figure 5B) is a plasma membrane
glycosylphosphatidylinositol-anchored glycoprotein that
tends to aggregate into rod-like structures. Recently,
PRNP has been shown to mediate the toxicity of other
pathological protein aggregates, including oligomers of
the amyloid β (Aβ) peptide, which are associated withAlzheimer’s disease PRNP [23,24]. It has been reported
that PRNP gene contributes the association between
the methionine/valine (M/V) polymorphism and risk
of Alzheimer disease [25].
Nuclear receptor interacting protein 1 (NRIP1 also
known as RIP140; 1.4-fold up-regulation; Figure 5B), is
a nuclear protein that specifically interacts with the
hormone-dependent activation domain AF2 of nuclear
receptors. NRIP1 is a key regulator that modulates tran-
scriptional activity of a variety of transcription factors,
including the estrogen receptor and has an important role
in regulating lipid and glucose metabolism. Mice devoid of
the co-repressor protein RIP140 are lean, show resistance
to high-fat diet-induced obesity and hepatic steatosis, and
have increased oxygen consumption [26]. Increased RIP140/
NRIP1 level is associate with inflammation and disorders
of lipid and glucose metabolism in diabetic patients [27].
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http://www.biomedcentral.com/1752-0509/8/80SPEG (0.7-fold down-regulation; Figure 5B), also known
as aortic preferentially expressed gene-1 (APEG-1), was
down-regulated by TGRL lipolysis products. APEG-1
appears to be expressed only in highly differentiated
aortic smooth muscle cells (ASMC) in normal vessel walls
but it’s mRNA was down-regulated in dedifferentiated
ASMC in response to vascular injury [28].
TGRL lipolysis product-induced endothelial cell apoptosis
Histone deacetylase 9 (HDAC9; 1.7-fold up-regulation;
Figure 5C) plays a critical role in transcriptional regulation,
cell cycle progression, and developmental events. Histone
acetylation/deacetylation alters chromosome structure and
affects transcription factor access to DNA. Growth arrest
and DNA-damage-inducible, alpha (GADD45A; 2.8-fold
up-regulation; Figure 5C) and beta (GADD45B) genes
are the first well-defined p53 downstream genes. They
can be induced by multiple DNA-damaging agents
and stressful growth arrest conditions, such as IR and
UV radiation, and play important roles in the control
of cell cycle checkpoint, DNA repair processes, and
signalling transduction. The protein encoded by this
gene responds to environmental stresses by mediating
activation of the p38/JNK pathway via MTK1/MEKK4
kinase. No change in GADD45A and loss function of
GADD45B suggested that its normal role in the pitu-
itary includes acting as a brake to cell proliferation
and survival [29].
Despite their central position in the TGRL-centered PPI
network, Mouse double minute 2 homolog (MDM2) and
S100 calcium binding protein B (S100B) were not found to
be differentially regulated in our samples (p-value > 0.05;
Figure 5C). MDM2 is a target gene of the transcription
factor tumor protein p53 and also affects the cell
cycle, apoptosis, and tumorgenesis through interactions
with other proteins. Over expression of this gene results
in excessive inactivation of tumor protein p53, diminish-
ing its tumor suppressor function. S100B is a member of
the S100 family of proteins containing 2 EF-hand calcium-
binding motifs. S100 proteins are localized in the cytoplasm
and/or nucleus of a wide range of cells, and involved
in the regulation of a number of cellular processes
such as cell cycle progression and differentiation. The
altered expressions of this gene have been implicated
in several neurological, neoplastic, and other types of
diseases, including Alzheimer’s disease.
In contrast, the High mobility group box 2 (HMGB2)
was up-regulated 1.7-fold by TGRL lipolysis (Figure 5C).
HMGB2 gene encodes a member of the non-histone
chromosomal high mobility group protein families. In
vitro studies have demonstrated that this protein is
able to efficiently bend DNA and form DNA circles.
HMGB2 is known to stabilize p53 in HeLa cells
[30]. Overexpression of HMGB2 in hepatocellularcarcinoma is associated with poor prognosis and tumor
development [31].
TGRL lipolysis product-induced metabolism and signalling
pathways
UDP-glucose 6-dehydrogenase (UGDH, 1.2-fold up-
regulation (p = 0.06); Figure 5D), the protein encoded by
this gene converts UDP-glucose to UDP-glucuronate and
thereby participates in the biosynthesis of glycosaminogly-
cans such as hyaluronan, chondroitin sulfate, and heparan
sulfate. The expression of UGDH is up-regulated by trans-
forming growth factor beta and down-regulated by hypoxia.
Catenin (cadherin-associated protein), beta 1 (CTNNB1,
0.8-fold down-regulation; Figure 5D), protein encoded by
this gene is part of a complex of proteins that constitute
adherens junctions (AJs). AJs are necessary for the creation
and maintenance of cell layers by regulating cell growth
and adhesion between cells.
The A-kinase anchor protein 5 (AKAP5), a member of
the AKAP family and also known as AKAP75 or AKAP79.
AKAP5 is predominantly expressed in cerebral cortex and
may anchor the PKA protein at postsynaptic densities
(PSD) and be involved in the regulation of postsynaptic
events. It can bind to the RII-beta regulatory subunit
of cAMP-dependent protein kinase (PKA), and also to
protein kinase C and the phosphatase calcineurin [32].
AKAP5/AKAP79 is present in the lipid raft of stimulated
KG1 cells [33]. Down–regulation of AKAP5 in HBMVEC
by TGRL lipolysis products suggests calcineurin-dependent
NFAT signalling may involve. Retinoic acid receptor,
beta (RARβ), a member of the thyroid-steroid hormone
receptor superfamily of nuclear transcriptional regulators
was increased 1.3-fold but was not significant. It binds ret-
inoic acid, which mediates cellular signalling in embryonic
morphogenesis, and cell growth and differentiation. This
protein limits growth of many cell types by regulating
gene expression. The mechanism associated with modula-
tion of ERK 1/2 and JNK activation and depends on
stimulation of RARβ [34].
To gain a better insight on the biological processes,
cellular components and molecular functions that are
affected by the differentially expressed genes, we per-
formed a functional analysis by using the DAVID toolbox
(see Methods) [35,36]. As shown in Figure 6, negative
regulation of transcription and biosynthetic processes
were highly enriched, as well as the positive regulation of
apoptosis and intracellular signalling. Not surprisingly,
given the implicated metabolic compounds, membrane-
related components and various organelles were the most
differentially expressed genes were localized. In agreement
with our analysis above, the functional enrichment ana-
lysis shows a clear differential regulation of transcriptional
units, including transcription factor and cofactor binding,
repressor activity and enzyme binding.
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The most significant discovery of this study is the robust
and rapid induction of genes encoding transcription factors,
inflammation, and apoptosis. More specifically, HBMVEC
treated with TGRL lipolysis products encode transcription
factor ATF3-related genes in the MAP Kinase pathway
associated with AP-1 signalling. This, then, stimulates an
array of pro-inflammatory and pro-apoptotic genes that
effect endothelial cell injury. ATF3 can be induced by stress
and growth factors in mammalian cells, and is thought to
play an important role in the cardiovascular and nervous
system. However, little is currently known about how the
induction of ATF3 is regulated, except that the JNK path-
way is involved. Previous studies have shown up-regulation
of ATF3 to act as either pro-inflammatory [37] or anti-
inflammatory [38-40] and it was more recently linked to
Alzheimer’s disease through a system-level approach [41].
ATF3 belongs to the ATF/cyclic AMP responsive elementbinding (CREB) family of transcription factors, character-
ized by a basic region leucine zipper (bZip) motif. The basic
region is necessary for binding to the ATF/CRE promoter
and the leucine zipper element for homo-and hetero-
dimerization with other bZip proteins to differentially regu-
late transcription. The dimeric state of ATF3 gives us clues
as to the ultimate effects of ATF3 on inflammation. As a
homo-dimer, ATF3 acts as a transcriptional regulator inhi-
biting expression of pro-apoptotic molecules. Alternatively,
ATF3 can form a heterodimer with activated c-Jun that
enhances transcription of stress response genes [42]. The
transcription of ATF3 as a key response gene after treat-
ment for 3 hr with TGRL lipolysis products demonstrated
that its induction was essential for the expression of
a subset of pro-inflammatory responses.
TGRL lipolysis products-induced signalling pathways
involve in mitogen-activated protein (MAP) Kinase,
TGF-β and p53 signalling. The four major MAP Kinase
Aung et al. BMC Systems Biology 2014, 8:80 Page 10 of 15
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activating phosphorylations of nuclear transcription
factors. Of these, ERK has been shown to inhibit
ATF3 expression while JNK activates ATF3 through
transcriptional regulation [43]. JNK activation also results
in phosphorylation of c-Jun, a component with ATF3 of a
complex that binds AP-1 responsive promoter regions. As
would be expected, c-Jun/AP-1, ATF2, ATF4, ATF6, CREB,
Myc, C/EBPB, Erg-1, and other transcription factors have
been shown to induce ATF3 expression [44,45].
Our study has shown that increased expression of
ATF3 occurs early in response to stress by a mechanism
requiring the related bZIP transcriptional regulator ATF4.
ATF3 contributes to induction of the apoptosis-inducing
protein DDIT3 transcriptional factor in response to TGRL
lipolysis products at 3 hr. DDIT3, CHOP, or GADD153
protein functions as a dominant-negative inhibitor by
forming heterodimers with other C/EBP members, such as
C/EBP and is linked to diabetes [13,46,47]. Expression of
transcriptional activators ATF4 and CHOP have been
reported to be induced during ER stress [48]. Although
ATF3, ATF4, and DDIT3 (CHOP) are co-ordinately
expressed in response to ER stress, there are differences
between these genes regarding the contribution of tran-
scriptional control and the timing of induced expression.
Previous studies have shown up regulation of ATF3 to
act as either pro-inflammatory [37] or anti-inflammatory
[38-40]. The dimeric state of ATF3 gives us clues as to the
ultimate effects of ATF3 on inflammation. As a homo-
dimer, ATF3 acts as a transcriptional regulator inhibiting
expression of pro-apoptotic molecules. Alternatively, ATF3
can form a heterodimer with activated c-Jun that enhances
transcription of stress response genes [42]. A number of
other biological molecules and pathways could contribute
to the pro-inflammatory and pro-apoptotic effects of
TGRL lipolysis products. In this study, mRNA levels of a
number of inflammatory genes were markedly up-
regulated in TGRL lipolysis products treated HBMVEC.
These genes, including IL-8, CXCL-3, PRNP and NRIP1,
are important cytokines, which participate in inflammatory
cell mobilization and recruitment. Induction of plasma
membrane PRNP suggested that PRNP interact with many
other proteins and induced vascular inflammation. It was
recently shown that unfolded protein response and ATF3
are associated with inflammation response related to ath-
erosclerosis in endothelial cells [49,50]. Our previous stud-
ies have shown that TGRL lipolysis products activate stress
response pathways that induce expression of multiple
pro-inflammatory and pro-apoptotic genes leading to
endothelial dysfunction [5,51].
TGRL lipolysis products-induced up regulation of
HDAC9 suggested vascular inflammation in brain micro-
vascular endothelial cells. Several studies elucidated that
the effects of individual HDACs in vasculature. HDAC9promotes angiogenesis and determines the angiogenic
gene expression pattern of endothelial cells [52]. Although
HDAC9 gene is significantly associated with large-vessel
stroke risk in different population [53], it’s actions are
not known in microvascular endothelial cells. Our
study showed up-regulation of HDAC9, GADD45A and
HMGB2 expression regulates cell cycle progression
through p53 signalling by TGRL lipolysis products in
HBMVEC. Additionally, up-regulation of RARβ and JNK,
may play a role and further activate vascular inflammation
and apoptosis in HBMVEC. Further studies are needed
to validate the strength of our system biology analyses
and to determine how TGRL lipolysis products regulate
physiologically important cell signalling pathways. The
marked increased expression of ATF3 suggested that up-
stream molecules, such as TGFβ suggest that the mitogen-
activated protein kinase pathway activation in HBMVEC
by TGRL lipolysis products is mediated through RARβ.
Lipolysis of TGRL produces an array of remnant
lipoprotein particles, fatty acids, phospholipids, diglycerides,
and monoglycerides [4]. Any and all of these lipids and
lipoproteins could have either pro- or anti-inflammatory
effects on the endothelial cells although our previous
work suggest that it is the fatty acids that are the primary
mediators of endothelial cell injury at high physiological
or pathophysiological concentrations [54-56]. However,
the broad activation of transcription factors and pro-
inflammatory genes suggests that other components of
TGRL lipolysis products also could be playing a part in
addition to fatty acids.
The peak elevation in blood TGRL is about 3–4 hours
after a meal and blood triglycerides can rise 0.3-fold to
many-fold higher during the postprandial period. Lipolysis
of TGRL by endothelial cell-associated lipoprotein lipase
likewise peaks in the postprandial period thus producing
more endothelial cell injury or lipotoxicity as a result
of the release of TGRL lipolysis products directly on
the endothelial cells. Rather than low-grade, chronic
injury, endothelial cells are injured repetitively over
the course of a day, which could be a more pathological
form of injury.
The precise pathogenetic mechanisms associated
with lipotoxic neurovasclular inflammation remain to
be elucidated. These experiments confirm the results
of our previous work showing that high physiological
to pathophysiological concentrations of TGRL lipolysis
products induce brain microvascular lipotoxicity resulting
in endothelial cell injury and apoptosis. These effects
could alter blood–brain barrier integrity allowing not
only potentially injurious lipids access to the brain,
but also enabling thrombosis to occur on the injured
brain endothelium causing brain microinfarctions. Thus,
neurovascular lipotoxicity could induce brain injury and
resulting decline in cognitive function.
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us possible clues involving cell signalling pathways in
HBMVEC treated with TGRL lipolysis products. The
systems biology approach that was taken in this study
allows to identify statistically significant associations by
using a consensus analysis of 4 different methods, as
well as looking simultaneously at the transcriptional,
protein-protein interaction and gene ontology networks.
Using a supervised interaction inference methodology
that exploits the experimentally identified interactions
that are known so far, is likely to increase the true positive
rate of our analysis when compared to unsupervised
methods. An extension to this work is looking at how infor-
mation propagates through the combined gene regulatory
and signal transduction networks by applied information-
based methodologies [57-60]. Our methodology will benefit
substantially from increasing the number of biological repli-
cates and the use of next-generation sequencing technolo-
gies (RNA-Seq) with appropriate coverage and depth, as in
this study, mRNA of the control and treated groups were
pooled (n = 3), while the confirmation by RT-PCR was done
on individual samples (n = 3) in each of the groups. Despite
this limitation, we were able to confirm approximately 50%
of the genes that were predicted by our computational
analyses to be implicated in this phenomenon.
Conclusions
Our systems biology approach demonstrated a robust
and rapid induction of genes encoding transcription factors,
inflammation, and apoptosis. Specifically, HBMVEC treated
with TGRL lipolysis products encode transcription factor
ATF3-related genes in the MAP kinase pathway associated
with AP-1 signalling, which stimulates an array of
pro-inflammatory and pro-apoptotic genes that effect
endothelial cell injury. These experiments confirm the
results of our previous work and demonstrate the com-
plex, parallel, and multifaceted aspects of cell signalling
that high physiological to pathophysiological concentra-
tions of TGRL lipolysis products induce in brain micro-
vascular lipotoxicity resulting in endothelial cell injury and
apoptosis. Future studies are needed to show if these
neurovascular pathophysiological processes are associated
with the development of cognitive impairment.
Methods
Human TGRL isolation: Postprandial blood samples were
obtained 3.5 h after consumption of a moderately high-fat
meal, which generally corresponds to the peak elevation in
plasma triglyceride concentrations. Triglyceride-rich
lipoproteins (TGRL) were isolated from human plasma at
a density of less than 1.0063 g/mL following an 18 h
centrifugation at 40,000 rpm in a SW41 Ti swinging
bucket rotor (Beckman Coulter, Sunnyvale, CA) held at
14°C within a Beckman L8-70 M (Beckman) ultracentrifuge.The top fraction (TGRL) was collected and dialyzed in
Spectrapor membrane tubing (mol wt cut off 3,500;
Spectrum Medical Industries, Los Angeles, CA) at 4°C
overnight against a saline solution containing 0.01%
EDTA. This protocol was approved by the Human Subjects
Review Committee at the University of California Davis.
Cell culture and lipid treatments
Human brain microvascular endothelial cells (HBMVEC)
(passage 6, Cell Systems, Kirkland, WA) were cultured in
CSC Complete Medium which includes 10% serum
(4Z0-500) (Cell Systems, Kirkland, WA) under an atmos-
phere of 5% CO2: 95% air at 37°C. Lipoprotein lipase (LpL)
(L2254) was purchased from Sigma, St. Louis, MO. 3´ IVT
Express Kit was purchased from Affymetrix, Santa Clara,
CA. Cells were exposed for 3 hr to the following conditions,
media, TGRL (150 mg/dL =1.5 mg/mL), lipoprotein lipase
(LpL) (2 U/mL), and TGRL lipolysis product (TGRL
(150 mg/dL) + LpL (2 U/mL)). The final concentration of
TGRL, LpL and TGRL lipolysis products were diluted in
media and pre-incubated for 30 minute at 37°C prior to
application. After incubation, cells were washed with cold
PBS and further process for RNA extraction.
RNA extraction and synthesis of biotin-labeled RNA
Total RNA was extracted from Media, LpL, TGRL, and
TGRL lipolysis products in HBMVEC in 6-well plate
using RNeasy Mini Kit (Qiagen) including the DNA
digestion step as described by the manufacturer.
Microarray experiments were performed with pooled
RNA isolates from each treatment group.
GeneChip analyses
GeneChip analyses of the pooled total RNA samples
(n = 3 per group for Media, LpL, TGRL, and TGRL
lipolysis products treatments) were performed as previously
described [5,61]. A 200 ng aliquot of total RNA from each
pooled sample was reverse-transcribed, followed by aRNA
Amplification, reverse transcription to synthesize first-
strand cDNA, second-strand cDNA Synthesis, in vitro
transcription to synthesize labeled aRNA, purification and
fragmentation of aRNA as described in the Affymetrix 3´
IVT Express Kit protocol (Affymetrix, Santa Clara, CA).
The fragmentation of labeled aRNA samples were hybrid-
ized to Human Genome U133A 2.0 Array high-density
oligonucleotide arrays with ~22,000 probe sets representing
14,500 well-characterized human genes (Affymetrix). The
hybridization, washing, labeling, and scanning of the
GeneChips were performed as described in the Affymetrix
protocols by the Microarray Core Facility in the UC Davis
Genome and Biomedical Sciences Facility. The microarray
dataset was deposited to Gene Expression Omnibus (GEO)
with accession ID GSE57526.
Aung et al. BMC Systems Biology 2014, 8:80 Page 12 of 15
http://www.biomedcentral.com/1752-0509/8/80Validation of changes in mRNA expression by
quantitative RT-PCR (qRT-PCR)
Since GeneChip analysis was done on pooled samples
from each experimental group, confirming qRT-PCR
analyses were performed on individual aliquots of total
RNA samples from each treatment replicate. The pur-
pose of these analyses was to evaluate the reliability of
GeneChip data and develop statistical data to validate the
changes suggested by the GeneChip assay of pooled RNA
samples as our previous study as two assays may not match
quantitatively but they always match qualitatively. Two
analytical procedures may contribute to these discrepancies.
1) Total RNA samples used for the PCR assay are different
from those used for the microarray assays. 2) The method
of hybridization and detection for the two assays are
different; the microarray assay utilizes hybridization of frag-
mented cRNA generated by Affymetrix protocols, whereas
the RT-PCR utilizes amplification of DNA fragments using
specific primer sets designed by a different method.
An aliquot equivalent to 5 μg of total RNA extracted
from each sample was reverse-transcribed to obtain
cDNA in a final volume of 20 μl solution consisting of
buffer, oligo-dT primer, DTT, dNTPs, and Superscript-
III reverse transcriptase (Invitrogen). RT-PCR with SYBR
as fluorescent reporter was used to quantify the expression
of selected genes identified by GeneChip analysis. Specific
primers (Additional file 1: Table S1) were designed with
Primer Express 1.0 software (Applied Biosystems) using the
gene sequences obtained from Affymetrix Probeset IDs.
Reactions were carried out in 384-well optical plates
containing 25 ng RNA in each well. The quantity of applied
RNA was normalized by simultaneously amplifying cDNA
samples with glyceraldehyde-3-phosphate dehydrogenase
(GAPDH)-specific primers. The transcript levels were
measured by real-time RT-PCR using the ABI Vii7
Sequence detection system (PE Applied Biosystems, Foster
City, CA). The PCR amplification parameters were: initial
denaturation step at 95°C for 10 min followed by 40 cycles,
each at 95°C for 15 s (melting) and 60°C for 1 min
(annealing and extension). A comparative threshold cycle
(Ct) method [62] was used to calculate relative changes in
gene expression determined from real-time quantitative
PCR experiments [Applied Biosystems user bulletin no. 2
(P/N4303859)]. The Ct, which correlates inversely with the
target mRNA levels, was measured as the cycle number at
which the SYBR Green emission increases above a preset
threshold level. The specific mRNA transcripts were
expressed as fold difference in the expression of the specific
mRNAs in RNA samples from the TGRL lipolysis-treated
cells compared with those from the control-treated cells.
Analysis and differential expression
In conjunction with the AFFY Bioconductor package
[63], we used several methods to extract the expressionprofiles and normalize the data. These include the BGX8
and mmgMOS [64] algorithms that take into account
both perfect-match (PM) and mismatch (MM) probes to
increase the statistical significance of the findings. To
identify the differential expression (DE) profiles among
the four conditions, we used the PUMA [65], PPLR [66]
and iPPRL [67] packages. In addition we considered the
popular MAS5 and RMA methods, although the later do
not take into account the MM probes, which decrease
the confidence level of the results.
Functional and PPI networks
We used probabilistic Bayesian methods via an open-source
package that uses Gene Ontology (GO) and KEGG
annotations to create a functional gene network from
microarray expression profiling data [68]. We integrated
the expression-derived relationships with the known
protein-protein interaction (PPI) network that was
extracted with BIONET Bioconductor package [6] and by
using an established base network (Interactome Library
[7]). We then used the DAVID (The Database for Annota-
tion, Visualization and Integrated Discovery) tool [35,36]
to extract functional annotation terms enriched in the top
550 differentially expressed genes with respect to the
control. We analyzed up- and down- regulated genes
independently. Gene Ontology (GO) terms such as cellular
components, molecular functions and biological processes
were considered. We select the number of significant
functional annotation terms produced from DAVID for
each gene set based on the following criteria: (a) we only
consider terms which include at least 2.5% of the gene set
and (b) we consider terms to be statistically significant if
they have a Benjamini-adjusted p-value less than 0.05.
Highly related annotation terms (k > 0.9) are grouped by
the term with the most genes and by their parent terms.
Only terms in the GO FAT category are selected in order
to filter out the very broad ones (Figure 6).
Gene regulatory network inference
After literature curation, we created a dataset of all
known transcription factor (TF)-gene interactions in
human cells, with more than 4,000 experimentally validated
interactions. Microvascular endothelial cell specific experi-
ments [69-75] account for less than 5% of the connections
we currently use in the training phase and are not adequate
for training, as this would radically limit the scope of the
method in finding new connections than the already estab-
lished ones. Thus, the whole set of interactions was used as
the training set for supervised learning through SIRENE
[8], which uses support vector machines (SVM) [76] to
classify genes to specific transcription factor bins, based on
how related their expression pattern is to other genes
that are known to be regulated by a specific TF. The
resulting condition-specific Gene Regulatory Network
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further enhanced by the regulatory predictions derived
(repression/activation) by using Pearson correlation
coefficient (PCC) on the expression profiles of the
participants in each of the inferred connections regulator-
target pair.
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